Company Profile
Oculis Stock Price, News & Analysis
- Ticker:
- OCS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Switzerland with U
Stock performance
12.38 USD (+2.57%)
Close
Last updated: August 6, 2026
742M USD
Market cap
Why the stock is moving
The latest monitored company update is “Oculis Reports Q2 2026 Financial Results and Provides Company Update.” The corresponding closing-price reaction is not yet available.
Company overview
Neuro-Ophthalmology Focus
Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation.
Privosegtor Neuroprotection
Privosegtor is a neuroprotective candidate being developed through the registrational PIONEER program for optic neuropathies. PIONEER-1 studies patients with optic neuritis, including those with and without multiple sclerosis, and the franchise may expand into acute multiple-sclerosis relapses and other neuro-axonal diseases.
Licaminlimab Precision Medicine
Licaminlimab is a topical anti-TNF-alpha antibody in the genotype-based PREDICT-1 registrational trial for dry eye disease. The program seeks to identify a genetically defined patient population more likely to respond to targeted anti-inflammatory treatment.
Future catalysts
Topline results from the PREDICT-1 registrational trial of Licaminlimab around year-end 2026.
IND submission for Privosegtor in acute multiple-sclerosis relapses in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Oculis (OCS)?
Oculis (OCS) most recently closed at 12.38 USD, a +2.57% move versus the previous session.
What is the market cap of Oculis (OCS)?
Oculis currently has a market capitalization of 742M USD on BioPharmSignal.
What does Oculis do?
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective candidate being...
On which exchange is OCS stock listed?
Oculis (OCS) is associated with NASDAQ, Switzerland with U, Biopharma.
What is PIONEER-1?
PIONEER-1 studies patients with optic neuritis, including those with and without multiple sclerosis, and the franchise may expand into acute multiple-sclerosis relapses and other neuro-axonal diseases.
Which conditions is Oculis targeting with PIONEER-1?
Oculis is associated with inflammatory disease, ophthalmology, genetic disease based on its company overview and current catalyst commentary.
How does Oculis describe recent progress with PIONEER-1?
Topline results from the PREDICT-1 registrational trial of Licaminlimab around year-end 2026. IND submission for Privosegtor in acute multiple-sclerosis relapses in the fourth quarter of 2026.
What is PREDICT-1?
Licaminlimab Precision Medicine Licaminlimab is a topical anti-TNF-alpha antibody in the genotype-based PREDICT-1 registrational trial for dry eye disease.